Your browser is no longer supported. Please, upgrade your browser.
MRTX Mirati Therapeutics, Inc. daily Stock Chart
Mirati Therapeutics, Inc.
Index- P/E- EPS (ttm)-7.13 Insider Own7.50% Shs Outstand43.83M Perf Week-2.32%
Market Cap8.24B Forward P/E- EPS next Y-8.80 Insider Trans-17.72% Shs Float40.85M Perf Month16.58%
Income-296.20M PEG- EPS next Q-1.97 Inst Own- Short Float11.02% Perf Quarter53.89%
Sales1.80M P/S4580.02 EPS this Y-78.70% Inst Trans0.15% Short Ratio11.29 Perf Half Y116.02%
Book/sh13.80 P/B13.70 EPS next Y-7.40% ROA-52.00% Target Price159.93 Perf Year148.90%
Cash/sh14.81 P/C12.77 EPS next 5Y- ROE-57.00% 52W Range66.01 - 203.77 Perf YTD46.70%
Dividend- P/FCF- EPS past 5Y-11.90% ROI- 52W High-7.23% Beta1.98
Dividend %- Quick Ratio11.30 Sales past 5Y- Gross Margin- 52W Low186.38% ATR8.88
Employees111 Current Ratio11.30 Sales Q/Q- Oper. Margin- RSI (14)63.66 Volatility5.05% 4.54%
OptionableYes Debt/Eq0.00 EPS Q/Q-49.70% Profit Margin- Rel Volume1.04 Prev Close194.89
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume398.58K Price189.04
Recom2.00 SMA207.15% SMA5020.13% SMA20067.47% Volume416,402 Change-3.00%
Sep-28-20Initiated BofA Securities Neutral $172
Sep-18-20Downgrade Citigroup Buy → Neutral $127 → $183
May-01-20Upgrade JP Morgan Neutral → Overweight $116
Apr-16-20Initiated Goldman Buy $151
Mar-12-20Upgrade JP Morgan Underweight → Neutral $88
Jan-28-20Initiated BMO Capital Markets Market Perform
Jan-27-20Initiated BMO Capital Markets Market Perform
Sep-24-19Upgrade Guggenheim Neutral → Buy $116
Sep-09-19Upgrade Jefferies Hold → Buy $89 → $105
Aug-02-19Downgrade JP Morgan Neutral → Underweight $85
Jul-18-19Initiated Deutsche Bank Hold $86
Jun-19-19Downgrade B. Riley FBR Buy → Neutral $60 → $92
Jun-07-19Downgrade Guggenheim Buy → Neutral
Jun-05-19Reiterated H.C. Wainwright Buy $84 → $117
Jun-04-19Upgrade Citigroup Neutral → Buy $76 → $132
Apr-17-19Initiated JP Morgan Neutral $72
Mar-25-19Initiated Credit Suisse Outperform $85
Mar-04-19Downgrade Citigroup Buy → Neutral $64 → $77
Feb-15-19Initiated Piper Jaffray Overweight $85
Dec-03-18Initiated B. Riley FBR Buy $60
Oct-17-20 01:57AM  
Oct-15-20 04:30PM  
Oct-14-20 04:06PM  
Oct-13-20 04:08PM  
Oct-12-20 09:45AM  
Oct-08-20 04:28PM  
Oct-06-20 02:55PM  
Oct-05-20 02:06PM  
Oct-01-20 04:40PM  
Sep-29-20 11:30AM  
Sep-18-20 04:16PM  
Sep-17-20 08:01AM  
Sep-15-20 05:00PM  
Sep-14-20 03:31PM  
Sep-11-20 02:16PM  
Sep-09-20 04:10PM  
Sep-08-20 08:34PM  
Sep-05-20 11:32AM  
Sep-04-20 05:01AM  
Sep-03-20 04:30PM  
Sep-01-20 08:00AM  
Aug-31-20 11:58PM  
Aug-25-20 03:08PM  
Aug-19-20 11:10AM  
Aug-14-20 08:00AM  
Aug-13-20 08:03AM  
Aug-12-20 09:57AM  
Aug-06-20 04:15PM  
Aug-04-20 12:32PM  
Aug-03-20 10:18AM  
Aug-02-20 06:53PM  
Jul-31-20 09:31AM  
Jul-30-20 01:09PM  
Jul-29-20 04:45PM  
Jul-27-20 12:31PM  
Jul-15-20 08:00AM  
Jul-14-20 12:50PM  
Jul-10-20 08:48PM  
Jul-06-20 04:52PM  
Jun-17-20 11:00AM  
Jun-16-20 10:09AM  
Jun-12-20 11:54AM  
Jun-06-20 11:31AM  
Jun-05-20 09:00AM  
Jun-03-20 09:45AM  
Jun-02-20 08:59PM  
Jun-01-20 09:07AM  
May-18-20 04:15PM  
May-15-20 08:06PM  
May-07-20 08:00PM  
May-05-20 08:41AM  
May-04-20 01:36PM  
Apr-27-20 12:32PM  
Apr-22-20 02:15PM  
Apr-21-20 04:19PM  
Apr-20-20 07:23AM  
Mar-26-20 01:06PM  
Feb-27-20 10:43AM  
Feb-25-20 08:00AM  
Feb-19-20 10:35AM  
Feb-15-20 11:30AM  
Jan-14-20 04:01PM  
Jan-09-20 10:00PM  
Jan-08-20 04:03PM  
Jan-07-20 07:57AM  
Jan-06-20 04:30PM  
Jan-03-20 01:36PM  
Jan-02-20 04:30PM  
Dec-26-19 11:11AM  
Dec-19-19 10:09AM  
Dec-18-19 08:40AM  
Dec-13-19 07:00AM  
Dec-04-19 08:35PM  
Nov-09-19 06:15PM  
Nov-04-19 06:55PM  
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. It is developing MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and sitravatinib, a spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. The company has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CARTER BRUCE L ADirectorAug 11Option Exercise6.782,25015,2554,250Aug 13 04:03 PM
CARTER BRUCE L ADirectorAug 11Sale126.412,250284,4282,000Aug 13 04:03 PM
FUCHS HENRY JDirectorAug 10Option Exercise20.5410,000205,40012,000Aug 11 05:36 PM
FUCHS HENRY JDirectorAug 10Sale131.3810,0001,313,7832,000Aug 11 05:36 PM
Braslyn Ltd.10% OwnerJun 12Option Exercise0.00600,0066003,135,972Jun 16 05:03 PM
Braslyn Ltd.10% OwnerJun 12Sale69.00600,00041,400,0002,535,966Jun 16 05:03 PM
CARTER BRUCE L ADirectorMay 18Option Exercise6.784,00027,1206,000May 20 05:10 PM
CARTER BRUCE L ADirectorMay 18Sale106.864,000427,4402,000May 20 05:10 PM
CHEN ISANEVP, Chief Medical OfficerMay 11Option Exercise24.9933,334833,01772,735May 13 04:18 PM
CHEN ISANEVP, Chief Medical OfficerMay 11Sale105.0033,3343,500,07039,401May 13 04:18 PM
BAUM CHARLES MPresident & CEOApr 27Option Exercise5.405573,008107,023Apr 28 08:49 PM
Johnson Craig ADirectorApr 20Option Exercise25.8415,000387,60017,000Apr 21 05:26 PM
Johnson Craig ADirectorApr 20Sale93.0015,0001,395,0002,000Apr 21 05:26 PM
BAUM CHARLES MPresident & CEOApr 17Option Exercise8.4940,000339,600146,466Apr 20 04:59 PM
BAUM CHARLES MPresident & CEOApr 17Sale90.3340,0003,613,109106,466Apr 20 04:59 PM
BAUM CHARLES MPresident & CEOMar 27Option Exercise5.402,29112,371106,466Mar 30 05:52 PM
Christensen JamieEVP, Chief Scientific OfficerMar 26Option Exercise15.518,058124,98332,842Mar 27 05:37 PM
BAUM CHARLES MPresident & CEOFeb 28Option Exercise5.402,29112,371104,175Mar 02 04:28 PM
BAUM CHARLES MPresident & CEOFeb 04Option Exercise15.414,68772,247101,884Feb 06 04:41 PM
CHEN ISANEVP, Chief Medical OfficerJan 29Option Exercise24.993,00275,02039,401Jan 31 08:03 PM
Boxer Capital, LLC10% OwnerJan 10Buy97.5050,0004,875,0001,765,560Jan 14 04:30 PM
BAUM CHARLES MPresident & CEODec 24Option Exercise24.933187,92756,917Dec 26 06:15 PM
Christensen JamieEVP, Chief Scientific OfficerDec 23Option Exercise5.446,66636,24613,326Dec 26 06:15 PM
Christensen JamieEVP, Chief Scientific OfficerDec 23Sale125.006,666833,2509,159Dec 26 06:15 PM
CARTER BRUCE L ADirectorNov 20Option Exercise6.783,00020,3403,000Nov 22 04:46 PM
CARTER BRUCE L ADirectorNov 20Sale94.743,000284,2200Nov 22 04:46 PM
GREY MICHAEL GDirectorNov 12Option Exercise16.843,50058,9405,298Nov 14 06:30 PM
GREY MICHAEL GDirectorNov 12Sale102.443,042311,6222,256Nov 14 06:30 PM